Ingenol Mebutate Patent Expiration
Ingenol Mebutate is Used for treating actinic keratosis by inhibiting proliferative activity of neoplastic cells and stimulating the immune system. It was first introduced by Leo Laboratories Ltd
Ingenol Mebutate Patents
Given below is the list of patents protecting Ingenol Mebutate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Picato | US9789078 | Method of topically treating actinic keratosis with ingenol mebutate cycle therapy | May 15, 2033 | Leo Labs |
| Picato | US8278292 | Therapeutic compositions | Jul 06, 2027 | Leo Labs |
| Picato | US8372827 | Therapeutic compositions | Dec 18, 2026 | Leo Labs |
| Picato | US8372828 | Therapeutic compositions | Dec 18, 2026 | Leo Labs |
| Picato | US8377919 | Therapeutic compositions | Dec 18, 2026 | Leo Labs |
| Picato | US8536163 | Therapeutic compositions | Dec 18, 2026 | Leo Labs |
| Picato | US8716271 | Therapeutic compositions | Dec 18, 2026 | Leo Labs |
| Picato | US8735375 | Therapeutic compositions | Dec 18, 2026 | Leo Labs |
| Picato | US9820959 | Therapeutic compositions | Dec 18, 2026 | Leo Labs |
| Picato | US9833428 | Therapeutic compositions | Dec 18, 2026 | Leo Labs |
| Picato | US9833429 | Therapeutic compositions | Dec 18, 2026 | Leo Labs |
| Picato | US9861603 | Therapeutic compositions | Dec 18, 2026 | Leo Labs |
| Picato | US6844013 | Methods of stimulating the immune system |
Dec 13, 2018
(Expired) | Leo Labs |
| Picato | US6432452 | Anti-cancer compounds |
Aug 19, 2018
(Expired) | Leo Labs |
| Picato | US6787161 | Anti-cancer compounds |
Aug 19, 2018
(Expired) | Leo Labs |
| Picato | US7410656 | Anti-cancer compounds |
Aug 19, 2018
(Expired) | Leo Labs |
Ingenol Mebutate's Family Patents
Explore Our Curated Drug Screens
Ingenol Mebutate Generic API Manufacturers
Several generic applications have been filed for Ingenol Mebutate.
Given below is the list of companies who have filed for Ingenol Mebutate generic, along with the locations of their manufacturing plants worldwide.
1. PADAGIS ISRAEL
Padagis Israel Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Ingenol Mebutate. Given below are the details of the strengths of this generic introduced by Padagis Israel.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.015% | gel | Discontinued | TOPICAL | N/A | Jan 7, 2019 |
| 0.05% | gel | Discontinued | TOPICAL | N/A | Jan 9, 2019 |
Manufacturing Plant Locations New
Padagis Israel's manufacturing plants are situated in 1 country - Israel. Given below are the details of these plant locations as well as the firm names of Padagis Israel as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| Israel |
| |||